Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

Ciltacabtagene autoleucel (cilta-cel) is an FDA-approved anti–B-cell maturation ... of CAR T-cell therapy. An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small ...

China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...

Brice and Amanda Dieter of Jamestown had their figurative worlds upended in October 2023. It was at this time that the ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

After the pathogen has been eradicated, most involved immune cells die a programmed cell death, and the immune response is down-regulated in an orderly fashion, leaving only a small number of ...

Imbruvica (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of Small Lymphocytic Lymphoma (SLL). It works by blocking BTK, a critical enzyme in B-cell receptor ...

A cancer is cured when there are no signs of cancer ... It starts in one of the testicles (testes), the small organs located in the scrotum. They produce the hormone testosterone, as well as ...